AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01497730 — intervention group
Intervention type: DEVICE
Intervention: Total Knee Replacement
Description: Subjects will receive one of the following total knee implants:~PFC Sigma Fixed Bearing (FB) cruciate retaining (CR), posterior stabilized (PS) or Rotating Platform CR or PS devices. LCS Rotating platform or PS devices. Triathlon CR, PS or mobile bearing devices. NexGen CR, LPS, LPS Flex FB PS, LPS Flex Mobile bearing, or LPS Mobile bearing devices.
Study NCT00819884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Oral suspension
Study NCT00961649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide ophthalmic suspension, 1%
Study NCT02852837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Intravenous (IV) infusion of 8 mg/kg or 16 mg/kg daratumumab.
Study NCT03193580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal Conventional tDCS
Description: tDCS will be applied for 20 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
Study NCT00961649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine tartrate ophthalmic solution, 0.2%
Study NCT00961649 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle
Description: Inactive ingredients used as placebo
Study NCT00961649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Inactive ingredients used as placebo
Study NCT03193580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal High Definition tDCS
Description: HD-tDCS will be applied for 20 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
Study NCT03193580 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: tDCS will be applied for 1 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
Study NCT00833703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Form: reconstituted solution using Clopidogrel powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight
Study NCT00833703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Form: reconstituted solution using matching placebo powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight
Study NCT00363298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextro-amphetamine
Description: dextro-amphetamine dosage form: 15 mg capsules, in Bottles A and B. Dosage: One capsule from Bottle A and one capsule from bottle B each morning. Frequency: once daily. Duration: 5 weeks.
Study NCT00363298 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Comparison
Description: caffeine dosage form: capsules identical to those in dextro-amphetamine arm, but containing 200 mg caffeine in Bottle A and 100 mg caffeine in Bottle B. Frequency: once daily. Duration: 5 weeks
Study NCT00663078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief CBT Group therapy
Description: CBT based therapy also expert patient programme
Study NCT02649309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPre
Description: Preconditioning 200 mmHg x 5 minutes before procedure
Study NCT02649309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham-Pre
Description: Sham 10 mmHg x 5 minutes before procedure
Study NCT02649309 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-Pre
Description: Sham 10 mmHg x 5 minutes before procedure
Study NCT02649309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPost
Description: Postconditioning 200 mmHg x 5 minutes after procedure
Study NCT01858571 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low dose chemotherapy
Description: Metronomic chemotherapy schedule : Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration) with each drug rounded off to the nearest tablet/capsule size.~Cycle A~* Daily oral Thalidomide (at 3mg/kg)~* Daily oral Celecoxib (100 mg BID for patients \< 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)~* Daily oral Etoposide (50 mg/m2/d)~Cycle B~* Daily oral Thalidomide (at 3mg/kg)~* Daily oral Celecoxib (100 mg BID for patients \< 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)~* Daily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days
Study NCT01858571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose chemotherapy
Description: Metronomic chemotherapy schedule : Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration) with each drug rounded off to the nearest tablet/capsule size.~Cycle A~* Daily oral Thalidomide (at 3mg/kg)~* Daily oral Celecoxib (100 mg BID for patients \< 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)~* Daily oral Etoposide (50 mg/m2/d)~Cycle B~* Daily oral Thalidomide (at 3mg/kg)~* Daily oral Celecoxib (100 mg BID for patients \< 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)~* Daily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days
Study NCT00776282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loratadine 10 mg orally disintegrating
Study NCT00776282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: loratadine 10 mg orally disintegrating
Study NCT02649309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham-Post
Description: Sham 10 mmHg x 5 minutes after procedure
Study NCT02649309 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-Post
Description: Sham 10 mmHg x 5 minutes after procedure
Study NCT03033784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8 International Units (IU) of Oxytocin
Description: Participants will receive one dose of intranasal oxytocin at a dose of 8IU.
Study NCT03033784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 24IU of Oxytocin
Description: Participants will receive one dose of intranasal oxytocin at a dose of 24IU.
Study NCT03033784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 48IU of Oxytocin
Description: Participants will receive one dose of intranasal oxytocin at a dose of 48IU.
Study NCT03033784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive an intranasal placebo to match the oxytocin doses.
Study NCT03033784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive an intranasal placebo to match the oxytocin doses.
Study NCT03484923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAG525
Description: 600 mg of LAG525 administered every 4 weeks intravenously
Study NCT03484923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: 400 mg of INC280 administered twice daily orally
Study NCT03484923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Description: 200 mg of ACZ885 administered every 4 weeks subcutaneosuly
Study NCT03484923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: 600 mg of LEE011 orally taken once daily on Days 1-21 of a 28-day cycle
Study NCT02458079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxiphylline
Study NCT01573429 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: deuterated-Bisphenol A (d-BPA)
Description: The primary endpoints are key pharmacokinetic measurements of d-BPA and d-BPA conjugates in blood and urine over 6 days after a single dose of oral and/or ethanol solution dermal application and/or a carboxymethylcellulose suspension dermal application of a dose of 100 micro g/kg bw of d-BPA.
Study NCT02458079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stool microbiota transplantation
Study NCT02053272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GWP42004
Description: The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).
Study NCT02053272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).
Study NCT02476981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Patients given remifentanil received continuous infusion of the drug at 1-5 µg/kg/h
Study NCT02476981 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil
Description: Patients given remifentanil received continuous infusion of the drug at 1-5 µg/kg/h
Study NCT02476981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients receiving dexmedetomidine were given that drug at 0.3-0.4 µg/kg over 10 min, followed by continuous infusion of 0.2 1 µg/kg/h
Study NCT02476981 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: Patients receiving dexmedetomidine were given that drug at 0.3-0.4 µg/kg over 10 min, followed by continuous infusion of 0.2 1 µg/kg/h
Study NCT03332056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belladonna and Opium
Study NCT03332056 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo suppository
Study NCT02995200 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accelerometer Based Feedback
Study NCT03618069 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CCI scanning (CTA, cardiac CT), and MRI scanning
Description: Scanning
Study NCT02476981 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: midazolam
Description: All patients were premedicated with midazolam 0.02 mg/kg before induction.
Study NCT02476981 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: propofol
Description: All patients in both groups received a bolus dose of propofol 0.3 mg/kg for sedative effect.
Study NCT01786148 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mobile phone application
Study NCT01786148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile phone application
Study NCT01743183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold
Description: The load adjustment was done weekly by a single examiner.
Study NCT02476981 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ephedrine
Description: Ephedrine 5 mg was injected when systolic blood pressure decreased below 90 mmHg
Study NCT01397071 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Avocado
Description: Fresh Avocado
Study NCT02353260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Hyperthermia
Description: treated with Therapeutic Ultrasound device on the 1st,3rd,5th,7th,9th day of each 21 day cycle
Study NCT03773419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texting Intervention (T-WRITE)
Description: Computer-based intervention, guided by a virtual therapist, that involves repeated listening, reading and writing sentences using a cellular phone
Study NCT03773419 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HandWriting Intervention (ORLA+WTG)
Description: Computer-based intervention, guided by a virtual therapist, that involves repeated listening, reading and writing sentences using pen and paper
Study NCT01839409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vestibular stimulation
Description: Physical activity and vestibular stimulation will be used in order to improve circadian rhythms
Study NCT02971839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-561
Study NCT02971839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02971839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVA
Study NCT02106806 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Zinc
Description: 35 mg of elemental zinc twice daily for 16 weeks
Study NCT02106806 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: 35 mg of elemental zinc twice daily for 16 weeks
Study NCT02106806 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: One capsule, twice daily for 16 weeks
Study NCT04730687 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional non surgical mechanical therapy
Description: Mechanical instrumentation in all groups was made with titanium Gracey curettes (8mm in diameter, Langer ½, item code: 7103, Kohler Medizintechnik, GmbH \& Co, Ltd, Stockach, Germany).
Study NCT04730687 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diode laser assisted non-surgical mechancal therapy
Description: One week after mechanical treatment, a 940 nm diode laser (Ezlase®, Biolase Technology, Inc., San Clemente, CA) with a 300 µm diameter optical fiber tip applied approximately 1 mm above the most apical part of the peri-implant pocket, parallel to the implant surface (E3-9 mm).
Study NCT04730687 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Er, Cr: YSGG laser-assisted non-surgical mechanical therapy
Description: 1 week after mechanical treatment, 2780 nm Er, Cr: YSGG laser (Waterlase®, Biolase Technology, Inc., San Clemente, CA), short pulse '' H '' with 500 µm diameter fiberoptic periodontal tip (RFPT5-14 mm) mode has been applied.
Study NCT00239590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Testosterone undecanoate
Description: Licensed for androgen deficiency
Study NCT00239590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate
Description: Licensed for androgen deficiency
Study NCT02106806 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule, twice daily for 16 weeks
Study NCT02772692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Squatting pan
Description: Using squatting pans to replace standard-sized toilets in one group of the included constipation patients
Study NCT02353260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel,Cisplatin,Fluorouracil
Description: Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2 cycles)
Study NCT02353260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel,Cisplatin,Fluorouracil
Description: Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2 cycles)
Study NCT01470573 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biological replacement corneal surface
Description: the expanded tissue will be applied to patient to replace the damaged ocular surface
Study NCT02085863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: laquinimod
Description: Oral laquinimod 0.6 mg capsules (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
Study NCT02085863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: laquinimod
Description: Oral laquinimod 0.6 mg capsules (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
Study NCT02085863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
Study NCT02085863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
Study NCT02295865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 60 mg
Description: Two tablets of JNJ-38518168, 30 milligram (mg) each for a total of 60 mg, orally, once daily.
Study NCT02295865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 30 mg
Description: One tablet of JNJ-38518168, 30 mg, orally, once daily.
Study NCT02295865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 3 mg
Description: One tablet of JNJ-38518168, 3 mg, orally, once daily.
Study NCT02295865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo either 30 mg tablet or 3 mg tablet will be administered orally.
Study NCT03592017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long-wavelength autofluorescence imaging
Description: Long-wavelength autofluorescence imaging will be performed with a prototype confocal scanning laser (cSLO) ophthalmoscope which will be equipped with additional laser sources and a reference for quantification of the signal. The experimental long-wavelength laser sources will be integrated into a custom-modified Spectralis HRA cSLO from Heidelberg Engineering. The additional laser sources will operate with long wavelength which are less energetic compared to the conventional short-wavelength lasers used currently for routine autofluorescence imaging. All safety standards have been considered and the light exposure for all imaging modes is well below the exposure limits for Class 1 and Class1M laser products as defined in the standard IEC 60825-1, edition 3.0, 2014-5.
Study NCT02989857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AG-120
Description: Tablet administered orally
Study NCT02989857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-120
Description: Tablet administered orally
Study NCT02989857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet administered orally
Study NCT03955978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSR-042
Description: -TSR-042 is administered intravenously via a 30-minute (-5-minute/+15-minute infusion window allowed) infusion
Study NCT03955978 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: -This trial will include image-guided brachytherapy with three-dimensional (3-D) treatment planning and in cases where pelvic radiation is deemed appropriate by the treating radiation oncologist, external beam radiation therapy (EBRT) using intensity modulated radiation therapy (IMRT) technique.
Study NCT03955978 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy
Description: -Prior to the start of treatment with TSR-042. If this biopsy yields insufficient tumor tissue, an archival sample may be requested, with Fraction 1 of brachytherapy, with Fraction 4 of brachytherapy
Study NCT03955978 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw for immune response
Description: -Prior to the start of any treatment, at the time of brachytherapy fractions 1 and 4 (corresponding to endometrial biopsy), prior to fourth dose of TSR-042, 6 weeks after the completion of all protocol related therapy
Study NCT05167708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforation
Description: flapless small punctures in the bone at direction of tooth movement to accelerate the movement.
Study NCT02811887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Description: A 12 week supervised and facility-based exercise training program. The program is facility based and supervised by a physiotherapist. The program runs 3 times weekly for 12 weeks. The exercise is group-based. The exercise program lasts approximately 1 hour and consists of a brief warm-up phase (bicycle ergometer at moderate intensity) followed by a circuit training program focusing on strength and endurance exercises of the large muscle groups (e.g. quadriceps).
Study NCT02811887 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise
Description: A 12 week supervised and facility-based exercise training program. The program is facility based and supervised by a physiotherapist. The program runs 3 times weekly for 12 weeks. The exercise is group-based. The exercise program lasts approximately 1 hour and consists of a brief warm-up phase (bicycle ergometer at moderate intensity) followed by a circuit training program focusing on strength and endurance exercises of the large muscle groups (e.g. quadriceps).
Study NCT02811887 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants allocated to usual care will receive instructions related to healthy living, alcohol absenteeism, and benefits of increased physical activity. The instructions will be provided by a physical therapist and/or a nurse, and will be given according to recommendations and local and national guidance. The participants are offered continued regular visits at the rehabilitation clinic, but no supervised physical exercise.